Adiponectin Levels and the Risk of Hypertension
Why the study?
Are higher plasma adiponectin levels associated with a reduced risk of hypertension in free-living adults?
Population
17,598 free-living adults (8,220 with hypertension) from 48 studies (43 nonprospective and 5 prospective)
Comparison
Higher plasma adiponectin levels vs Lower plasma adiponectin levels / normotensive…
Design
Meta-analysis
Authors
Discussion
Loading...
Member takes
Implication
Higher adiponectin may aid hypertension risk stratification; leaves open causal role and need for prospective trials.
Key Points
- To evaluate epidemiological evidence linking circulating plasma adiponectin levels to the risk of hypertension in free-living adult populations.
- Systematic review and meta-analysis of 48 studies (43 nonprospective, 5 prospective) identified via MEDLINE and EMBASE through February 2013, encompassing 17,598 adults (8,220 with hypertension; mean age 19–69 years; mean BMI 22–38 kg/m²).
- Calculated weighted mean differences in adiponectin using a random-effects model and evaluated dose-response associations per 1 µg/mL increase using two-stage generalized least-squares trend estimation.
- Adults with hypertension had 1.64 µg/mL lower plasma adiponectin levels compared to normotensive adults (weighted mean difference -1.64 µg/mL; 95% CI, -2.07 to -1.21).
- Each 1 µg/mL increase in plasma adiponectin was associated with a 6% reduced risk of hypertension (OR 0.94; 95% CI, 0.92 to 0.97), a protective trend that remained consistent across age, sex, and BMI strata (P > 0.05).
Structured PICO
Are higher plasma adiponectin levels associated with a reduced risk of hypertension in free-living adults?
P
Population
17,598 free-living adults (8,220 with hypertension) from 48 studies (43 nonprospective and 5 prospective)
I
Intervention
Higher plasma adiponectin levels
C
Comparator
Lower plasma adiponectin levels / normotensive adults
O
Outcome
Hypertension
Higher plasma adiponectin levels are associated with a reduced risk of hypertension, suggesting it may serve as a biomarker and potential mediator in adiposity-related hypertension.
Limitations
- unexplained large between-study heterogeneity
- small number of prospective studies
- selective reporting of dose-response data
Cite This Study
Kim et al. (2013) studied this question.